These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33358561)

  • 1. Maximizing Tumor Control and Limiting Complications With Stereotactic Body Radiation Therapy for Pancreatic Cancer.
    Mahadevan A; Moningi S; Grimm J; Li XA; Forster KM; Palta M; Prior P; Goodman KA; Narang A; Heron DE; Lo SS; Urbanic J; Herman JM
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):206-216. PubMed ID: 33358561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor Control Probability Modeling and Systematic Review of the Literature of Stereotactic Body Radiation Therapy for Prostate Cancer.
    Royce TJ; Mavroidis P; Wang K; Falchook AD; Sheets NC; Fuller DB; Collins SP; El Naqa I; Song DY; Ding GX; Nahum AE; Jackson A; Grimm J; Yorke E; Chen RC
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):227-236. PubMed ID: 32900561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stereotactic Body Radiation Therapy for Spinal Metastases: Tumor Control Probability Analyses and Recommended Reporting Standards.
    Soltys SG; Grimm J; Milano MT; Xue J; Sahgal A; Yorke E; Yamada Y; Ding GX; Li XA; Lovelock DM; Jackson A; Ma L; El Naqa I; Gibbs IC; Marks LB; Benedict S
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):112-123. PubMed ID: 33516580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local Control After Stereotactic Body Radiation Therapy for Stage I Non-Small Cell Lung Cancer.
    Lee P; Loo BW; Biswas T; Ding GX; El Naqa IM; Jackson A; Kong FM; LaCouture T; Miften M; Solberg T; Tome WA; Tai A; Yorke E; Li XA
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):160-171. PubMed ID: 30954520
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer.
    Rajagopalan MS; Heron DE; Wegner RE; Zeh HJ; Bahary N; Krasinskas AM; Lembersky B; Brand R; Moser AJ; Quinn AE; Burton SA
    Radiat Oncol; 2013 Oct; 8():254. PubMed ID: 24175982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.
    Chuong MD; Springett GM; Freilich JM; Park CK; Weber JM; Mellon EA; Hodul PJ; Malafa MP; Meredith KL; Hoffe SE; Shridhar R
    Int J Radiat Oncol Biol Phys; 2013 Jul; 86(3):516-22. PubMed ID: 23562768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal Radiation Therapy Fractionation Regimens for Early-Stage Non-Small Cell Lung Cancer.
    Liu F; Ververs JD; Farris MK; Blackstock AW; Munley MT
    Int J Radiat Oncol Biol Phys; 2024 Mar; 118(3):829-838. PubMed ID: 37734445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant stereotactic body radiation therapy for nonmetastatic pancreatic adenocarcinoma.
    Jiang W; Haque W; Verma V; Butler EB; Teh BS
    Acta Oncol; 2019 Sep; 58(9):1259-1266. PubMed ID: 31237185
    [No Abstract]   [Full Text] [Related]  

  • 9. Conventionally fractionated radiation therapy versus stereotactic body radiation therapy for locally advanced pancreatic cancer (CRiSP): An international systematic review and meta-analysis.
    Tchelebi LT; Lehrer EJ; Trifiletti DM; Sharma NK; Gusani NJ; Crane CH; Zaorsky NG
    Cancer; 2020 May; 126(10):2120-2131. PubMed ID: 32125712
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma.
    Liu F; Brown DR; Munley MT
    Radiother Oncol; 2024 May; 194():110223. PubMed ID: 38467342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeling of Tumor Control Probability in Stereotactic Body Radiation Therapy for Adrenal Tumors.
    Stumpf PK; Yorke ED; El Naqa I; Cuneo KC; Grimm J; Goodman KA
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):217-226. PubMed ID: 33864824
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Re-irradiation stereotactic body radiotherapy for spinal metastases: a multi-institutional outcome analysis.
    Hashmi A; Guckenberger M; Kersh R; Gerszten PC; Mantel F; Grills IS; Flickinger JC; Shin JH; Fahim DK; Winey B; Oh K; John Cho BC; Létourneau D; Sheehan J; Sahgal A
    J Neurosurg Spine; 2016 Nov; 25(5):646-653. PubMed ID: 27341054
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patterns of Failure Following Preoperative Chemotherapy and Stereotactic Body Radiation Therapy and Resection for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer.
    Libbey N; Gallagher L; Cantalino J; Weinberg BA; Noel MS; He AR; Radkani P; Marshall JL; Weiner LM; Jackson PG; Fishbein TM; Winslow ER; Haddad N; Rashid A; Unger KR
    J Gastrointest Cancer; 2024 Jun; 55(2):852-861. PubMed ID: 38347342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1 Study of Stereotactic Body Radiation Therapy Dose Escalation for Borderline Resectable Pancreatic Cancer After Modified FOLFIRINOX (NCT01446458).
    Shaib WL; Hawk N; Cassidy RJ; Chen Z; Zhang C; Brutcher E; Kooby D; Maithel SK; Sarmiento JM; Landry J; El-Rayes BF
    Int J Radiat Oncol Biol Phys; 2016 Oct; 96(2):296-303. PubMed ID: 27475674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor Control Probability of Radiosurgery and Fractionated Stereotactic Radiosurgery for Brain Metastases.
    Redmond KJ; Gui C; Benedict S; Milano MT; Grimm J; Vargo JA; Soltys SG; Yorke E; Jackson A; El Naqa I; Marks LB; Xue J; Heron DE; Kleinberg LR
    Int J Radiat Oncol Biol Phys; 2021 May; 110(1):53-67. PubMed ID: 33390244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
    Holyoake DL; Ward E; Grose D; McIntosh D; Sebag-Montefiore D; Radhakrishna G; Patel N; Silva M; Mukherjee S; Strauss VY; Odondi L; Fokas E; Melcher A; Hawkins MA
    BMC Cancer; 2016 Sep; 16(1):728. PubMed ID: 27619800
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Applicability of the linear-quadratic formalism for modeling local tumor control probability in high dose per fraction stereotactic body radiotherapy for early stage non-small cell lung cancer.
    Guckenberger M; Klement RJ; Allgäuer M; Appold S; Dieckmann K; Ernst I; Ganswindt U; Holy R; Nestle U; Nevinny-Stickel M; Semrau S; Sterzing F; Wittig A; Andratschke N; Flentje M
    Radiother Oncol; 2013 Oct; 109(1):13-20. PubMed ID: 24183066
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.
    Courtney PT; Paravati AJ; Atwood TF; Raja N; Zimmerman CT; Fanta PT; Lowy AM; Simpson DR; Xu R; Murphy JD
    Int J Radiat Oncol Biol Phys; 2021 Jul; 110(4):1003-1012. PubMed ID: 33571625
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histology-driven hypofractionated radiation therapy schemes for early-stage lung adenocarcinoma and squamous cell carcinoma.
    Liu F; Farris MK; Ververs JD; Hughes RT; Munley MT
    Radiother Oncol; 2024 Jun; 195():110257. PubMed ID: 38548113
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose Escalation in Stereotactic Body Radiation Therapy for Pancreatic Cancer: A Meta-Analysis.
    Zaorsky NG; Lehrer EJ; Handorf E; Meyer JE
    Am J Clin Oncol; 2019 Jan; 42(1):46-55. PubMed ID: 29965809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.